Logo for CMSAF Leadership Library
Logo for CMSAF Leadership Library

Reoptimization for Great Power Competition

Logo for CMSAF Leadership Library

 

 
Department of the Air Force
 

 

 

LATEST NEWS

 

“We need these changes now; we are out of time to reoptimize our forces to meet the strategic challenges in a time of great power competition.”

~ Secretary of the Air Force Frank Kendall
 

Air Force & Space Force announce sweeping changes to maintain superiority amid Great Power Competition

The United States faces a time of consequence marked by significant shifts in the strategic environment. To remain ready, the U.S. Air Force must change.

In early 2024, the Department of the Air Force unveiled sweeping plans for reshaping, refocusing, and reoptimizing the Air Force and Space Force to ensure continued supremacy in their respective domains while better posturing the services to deter and, if necessary, prevail in an era of Great Power Competition. Through a series of 24 DAF-wide key decisions, four core areas which demand the Department’s attention will be addressed: Develop People, Generate Readiness, Project Power and Develop Capabilities.

Today, the Air Force once again finds itself at a critical juncture—an era of Great Power Competition marked by a new security environment, a rapidly evolving character of war, and a formidable competitor. This new era requires understanding its challenges and the attributes needed to succeed.

Embracing change is not a choice; it is a necessity. The Air Force must “reoptimize” into an enterprise prepared for high-end conflicts and long-term strategic competition.

 

U.S. Navy Surgeon General Message on Novavax
U.S. Navy Bureau of Medicine and Surgery
Video by BUMED PAO
Aug. 26, 2022 | 2:08
Video message by Rear Adm. Bruce Gillingham, Surgeon General of the Navy, on release of Novavax. In addition to the already approved Pfizer, Moderna, and Janssen COVID-19 vaccines, in July 2022 the Food and Drug Administration approved a new arrow in our quiver – Novavax. Novavax is a traditional vaccine that teaches the immune system to recognize the virus. It does not use any mRNA or DNA technology and it doesn’t enter the nucleus of cells. The vaccine uses a SARS-CoV-2 recombinant spike protein to produce an autoimmune reaction in order to protect against further infection. This vaccine has an E.U.A. – or Emergency Use Authorization – for all individuals 18 and over. This video was produced by the Visual Information Directorate, Naval Medical Leader & Development Command. More


Space Force Great Power Competition

 
Department of the Air Force